Boston Scientific (BSX)

For investors seeking high-potential stocks priced under $2, several companies stand out due to their innovative offerings, upcoming developments, or strategic positioning in the market. Here’s a look at five noteworthy companies to watch in addition to Sana Biotechnology (NASDAQSANA) and CS Diagnostics Corp. (OTCQB: CSDX) in January 2025.

The healthcare and technology sectors are experiencing unprecedented growth as companies push the boundaries of innovation to address critical global challenges. From revolutionary treatments for cardiovascular disease to AI-powered tools and cutting-edge medical devices, these advancements are reshaping industries and creating significant opportunities for investors. Market leaders and emerging innovators alike are driving transformative change, paving the way for a healthier, more connected future.

Today's market update highlights exciting developments across key companies demonstrating innovation, growth potential, and strategic progress. From dividend shares and stock splits to groundbreaking medical advancements, these companies offer compelling opportunities for investors to watch.

Boston Scientific Co (NYSEBSX) is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs.

Shares of Boston Scientific Corporation (NYSEBSX) traded at a new 52-week high today and are currently trading at $50.05. So far today, approximately 8.42M shares have been exchanged, as compared to an average 30-day volume of 9.04M shares.

Shares of Boston Scientific Corporation (NYSEBSX) traded at a new 52-week high today and are currently trading at $50.05. So far today, approximately 8.42M shares have been exchanged, as compared to an average 30-day volume of 9.04M shares.

Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases

CS Diagnostics Group (OTC: FZRO) signed a landmark agreement to sell and transfer tangible and intangible assets, including patents, for the CS Protect-Hydrogel to CS Diagnostics Corp. The hydrogel-based tissue spacer, designed for radiation therapy, increases the distance between healthy tissue and cancer cells, protecting healthy tissues from high radiation doses.

Boston Scientific Corporation (NYSEBSX), a global leader in medical device technology, announced to acquire Silk Road Medical, Inc. NASDAQ: SILKNASDAQSILK)

Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash

NORTHAMPTON, MA / ACCESSWIRE / September 21, 2023 / Boston Scientific

Shares of Boston Scientific Corporation (NYSEBSX) traded at a new 52-week high today and are currently trading at $54.52. So far today, approximately 3.79M shares have been exchanged, as compared to an average 30-day volume of 7.66M shares.

Boston Scientific Corporation (NYSEBSX) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 5.09% on the day to $53.34.

Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024

Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.

Shares of Boston Scientific Corporation (NYSEBSX) traded at a new 52-week high today and are currently trading at $50.05. So far today, approximately 8.42M shares have been exchanged, as compared to an average 30-day volume of 9.04M shares.

BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSEBSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.

Boston Scientific Corporation (NYSEBSX): RHYTHMIA HDx Mapping System by Boston Scientific Corporation is designed to offer unprecedented clarity, enabling physicians to enhance diagnostic efficiency. This advanced mapping system plays a pivotal role in delivering targeted therapy and successfully accomplishing the goals of heart procedures in intricate medical scenarios. Notably, the RHYTHMIA HDxMapping system achieves an impressive accuracy rate of 99.98%, accelerates mapping by a factor of 5 compared to standard systems, and generates 25 additional data points. Boston Scientific asserts that their mapping system stands as the exclusive provider of genuine high-resolution, high-definition, and automated mapping in the industry.

Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand.

3M settled the ear plug lawsuit, clearing the path forward. The stock offers investors a high yield and value that may be too hard to pass up

DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next.

Surgery centers and medtech firms see a surge in demand as joint replacements and other elective surgeries are rescheduled, causing challenges for insurers.

Intuitive Surgical (NASDAQISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning